In this newly published study from Mayo Clinic (Apr 2022), patients with obstructive sleep apnea (OSA) and comorbid cardiovascular disease (CVD) who were effectively treated for OSA were nearly $4,500 less expensive than those not adherent with their OSA treatment:
EnsoData, the leader in Al/ML for sleep, combines our technology with best-in-class care service partners to help payers and at-risk providers dramatically improve sleep apnea treatment success.
Sleep apnea is prevalent in 3 of 4 people with healthcare’s most common and expensive conditions. Untreated sleep apnea diminishes the impact of ANY intervention to improve outcomes for this population.